Lamotrigine-Associated Movement Disorder: A Literature Review

Background: Lamotrigine (LMT) is a phenyltriazine derivative that was originally described as an antiepileptic drug. Objective: This literature review aims to evaluate the clinical epidemiological profile, pathological mechanisms, and management of lamotrigine-associated movement disorders. Methods: Relevant reports in six databases were identified and assessed by two reviewers without language restriction. Reports that the individuals only developed tremor or ataxia after LMT use were not included. Results: In total 48 reports of 108 cases from 19 countries were assessed. The movement disorders associated with LMT found were 29 tics, 21 dyskinesias, 14 myoclonus, 13 parkinsonism, 10 dystonia, and 1 stuttering. The not clearly defined cases included 10 akathisia, 4 myoclonus, 4 cerebellar syndromes, 1 hypertonia, 1 dyskinesia, and an unknown number of dystonia cases. The mean reported age was 33.34 years (range: 1.574 years). The male was the predominant sex and the most common LMT indication was epilepsy. The mean LMT-dose at the movement disorder onset was 228 mg. The time from LMT start to the onset of movement disorder was within 6 months in 81%. The time from LMT withdrawal to complete recovery was within 1 month in 83%. The most common management was LMT withdrawal. Conclusions: In the literature, the majority of the cases did not give a clear picture of the individual, and the times of movement disorder onset and recovery are not described. We believe that before withdrawal LMT, a dose adjustment based on the benefits and adverse events with careful evaluation case-by-case can be done.

Automated summary

This literature review evaluated the clinical epidemiological profile, pathological mechanisms, and management of lamotrigine-associated movement disorders. A total of 108 cases from 48 reports in 19 countries were assessed, with various movement disorders associated with LMT being identified. Most cases showed onset of movement disorder within 6 months of LMT use, and recovery within 1 month of withdrawal, with LMT withdrawal being the most common management approach.